Werewolf Therapeutics (HOWL) Competitors $1.49 +0.04 (+2.76%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.67%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. RNAC, JBIO, TNXP, ALLO, AVIR, LYEL, FENC, ACIU, EDIT, and IMMPShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Cartesian Therapeutics (RNAC), Jade Biosciences (JBIO), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Atea Pharmaceuticals (AVIR), Lyell Immunopharma (LYEL), Adherex Technologies (FENC), AC Immune (ACIU), Editas Medicine (EDIT), and Prima BioMed (IMMP). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Its Competitors Cartesian Therapeutics Jade Biosciences Tonix Pharmaceuticals Allogene Therapeutics Atea Pharmaceuticals Lyell Immunopharma Adherex Technologies AC Immune Editas Medicine Prima BioMed Werewolf Therapeutics (NASDAQ:HOWL) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Which has more volatility and risk, HOWL or RNAC? Werewolf Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Is HOWL or RNAC more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf TherapeuticsN/A -111.87% -62.68% Cartesian Therapeutics N/A N/A -6.36% Do analysts recommend HOWL or RNAC? Werewolf Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 436.91%. Cartesian Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 323.73%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer HOWL or RNAC? In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 1 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.02 beat Cartesian Therapeutics' score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, HOWL or RNAC? Werewolf Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.88M36.24-$70.51M-$1.64-0.91Cartesian Therapeutics$38.91M6.31-$77.42M-$52.83-0.18 Do institutionals & insiders hold more shares of HOWL or RNAC? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryWerewolf Therapeutics beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.14M$3.15B$5.79B$10.47BDividend YieldN/A2.35%5.61%4.61%P/E Ratio-0.9120.9180.5026.81Price / Sales36.24415.21519.29119.31Price / CashN/A46.4637.6661.43Price / Book0.909.6015.756.39Net Income-$70.51M-$53.22M$3.30B$271.80M7 Day Performance4.20%3.11%5.37%3.49%1 Month Performance20.16%7.56%8.10%9.90%1 Year Performance-31.96%11.15%81.37%28.62% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.9626 of 5 stars$1.49+2.8%$8.00+436.9%-37.9%$68.14M$1.88M-0.9140Positive NewsGap UpHigh Trading VolumeRNACCartesian Therapeutics1.578 of 5 stars$9.79+1.1%$40.00+308.6%-42.9%$251.70M$1.03M-0.1964News CoverageJBIOJade Biosciences1.6912 of 5 stars$7.07-8.2%$16.00+126.3%N/A$251.23MN/A-0.2320Positive NewsTNXPTonix Pharmaceuticals3.1767 of 5 stars$27.75-3.0%$70.00+152.3%+73.4%$250.79M$10.09M-0.7050News CoverageALLOAllogene Therapeutics2.8254 of 5 stars$1.15+1.8%$8.44+634.3%-60.1%$250.73MN/A-1.04310AVIRAtea Pharmaceuticals1.995 of 5 stars$3.04-3.2%$6.00+97.4%-24.6%$249.18MN/A-1.8970News CoveragePositive NewsShort Interest ↑LYELLyell Immunopharma2.0743 of 5 stars$13.13+2.4%$15.00+14.2%-58.0%$246.29M$60K-0.54270FENCAdherex Technologies2.1319 of 5 stars$8.67-1.0%$13.33+53.8%+63.9%$244.50M$47.54M-20.6410News CoverageACIUAC Immune2.437 of 5 stars$2.48+2.1%$10.00+303.2%-33.6%$244M$31.02M-4.28140Positive NewsEDITEditas Medicine3.9524 of 5 stars$2.67-0.7%$5.10+91.0%-27.6%$241.88M$32.31M-0.94230IMMPPrima BioMed0.9526 of 5 stars$1.73+5.5%$7.00+304.6%-28.4%$240.73M$6.69M0.002,021News Coverage Related Companies and Tools Related Companies Cartesian Therapeutics Alternatives Jade Biosciences Alternatives Tonix Pharmaceuticals Alternatives Allogene Therapeutics Alternatives Atea Pharmaceuticals Alternatives Lyell Immunopharma Alternatives Adherex Technologies Alternatives AC Immune Alternatives Editas Medicine Alternatives Prima BioMed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts